- Abstract
10
- 10.1016/s1556-0864(23)00265-4
11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
- Apr 01, 2023
- Journal of Thoracic Oncology
- M Majem + 11 more +11